This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

March 18, 2021
Delivered DigitallyCentral European Time

Cognoptix

Profile

Cognoptix is a clinical-stage diagnostic/medical device company developing the Sapphire II system, a ground-breaking technology for the early detection and diagnosis of Alzheimer's Disease (AD). Cognoptix's mission is to provide clinicians with a reliable, non-invasive, affordable test that can be performed quickly in both specialist (neurologist, geriatric psychologist, ophthalmologist) and general practitioner offices to enable informed, swift intervention and ongoing monitoring of patients.

Company Background: Cognoptix was co-founded by AD pioneer and Cognoptix BOD and SAB member Dr. Lee Goldstein, at the Brigham and Women's Hospital in Boston. He and his team discovered the ability to measure, monitor, and detect Aβ aggregates, a hallmark of AD, in the lens of the eye. Initial autopsy studies at Harvard Univ. showed the presence of Aβ deposits are specific to the lens of AD patients and not found in other common neurological diseases like Parkinson's, frontotemporal dementia, progressive supranuclear palsy, Huntington's, or ALS, establishing the Sapphire II proof of concept.

Leadership: Dr. Wilke has a long, proven track record as an executive with extensive scientific, strategic development and management experience in the biotechnology, healthcare, and venture capital industries. Her passionate, driven management team is highly experienced in the healthcare and biotechnology industry with over 100 years of combined experience, including world-renowned experts in the fields of neurodegenerative research and diagnostics. The Company's world-class Scientific Advisory Board helps direct the development and commercialization of Sapphire II led by some of the top Alzheimer's scientists and physicians in the US. The Company's Board of Directors includes experienced life science entrepreneurs and investors.